Regeneron Pharmaceuticals faces challenges with Eylea but strong sales with Dupixent and gene therapy.

From Nasdaq: 2025-03-09 06:20:00

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) has seen a 30% drop in shares over the past year due to issues with its Eylea drug. However, the company’s eczema treatment Dupixent has been a strong performer, with global sales of $3.7 billion in the fourth quarter. Regeneron is also developing a promising gene therapy for deafness. Additionally, the company has announced a quarterly dividend of $0.88 and actively returns capital to shareholders through a stock buyback program. Analysts believe that Regeneron’s innovative pipeline and strong operations make it an attractive investment opportunity.

Regeneron’s recent struggles with Eylea have been offset by the success of Dupixent, with global sales of $3.7 billion in the fourth quarter. The company is also developing a promising gene therapy for congenital deafness. Regeneron has announced a quarterly dividend of $0.88 and actively returns capital to shareholders through a stock buyback program. With its innovative pipeline and strong operations, analysts believe Regeneron remains an attractive investment opportunity.



Read more at Nasdaq: 1 Dividend Stock Down 30% to Buy and Hold for the Next Decade